Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder

Perlis RH, Dowd D, Fava M, Lencz T, Krause DS.Depress Anxiety. 2020 Sep;37(9):834-841. doi: 10.1002/da.23029. Epub 2020 May 7.PMID: 32383277 Clinical Trial.

Efficacy and safety of TS-121, a novel vasopressin V 1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study

Kamiya M, Sabia HD, Marella J, Fava M, Nemeroff CB, Umeuchi H, Iijima M, Chaki S, Nishino I.J Psychiatr Res. 2020 Sep;128:43-51. doi: 10.1016/j.jpsychires.2020.05.017. Epub 2020 May 31.PMID: 32521250 Free article. Clinical Trial.

Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement.

Dodd S, Mitchell PB, Bauer M, Yatham L, Young AH, Kennedy SH, Williams L, Suppes T, Lopez Jaramillo C, Trivedi MH, Fava M, Rush AJ, McIntyre RS, Thase ME, Lam RW, Severus E, Kasper S, Berk M.

World J Biol Psychiatry. 2017 Oct 6:1-19. doi: 10.1080/15622975.2017.1379609. [Epub ahead of print]

From depression to anxiety, and back.

Bui E, Fava M.

Acta Psychiatr Scand. 2017 Oct;136(4):341-342. doi: 10.1111/acps.12801. Epub 2017 Sep 2. No abstract available.

Lessons Learned From the VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) Study.

Fava M.

JAMA. 2017 Jul 11;318(2):126-128. doi: 10.1001/jama.2017.8030. No abstract available.

Use of band-pass filter analysis to evaluate outcomes in an antidepressant trial for treatment resistant patients.

Targum SD, Burch DJ, Asgharnejad M, Petersen T, Gomeni R, Fava M.

Eur Neuropsychopharmacol.2014 Jun 17. pii: S0924-977X(14)00171-0. doi: 10.1016/j.euroneuro.2014 Aug; 24(8):1188-1195.

Circulating microRNAs as biomarkers for depression: Many candidates, few finalists.

Yuan H, Mischoulon D, Fava M, Otto MW.

J Affect Disord. 2017 Jun 27. pii: S0165-0327(16)32446-6. doi: 10.1016/j.jad.2017.06.058. [Epub ahead of print] Review.

Guidelines for the recognition and management of mixed depression.

Stahl SM, Morrissette DA, Faedda G, Fava M, Goldberg JF, Keck PE, Lee Y, Malhi G, Marangoni C, McElroy SL, Ostacher M, Rosenblat JD, Solé E, Suppes T, Takeshima M, Thase ME, Vieta E, Young A, Zimmerman M, McIntyre RS.

CNS Spectr. 2017 Apr;22(2):203-219. doi: 10.1017/S1092852917000165. Epub 2017 Feb 28. Review.

Is the Noradrenergic Symptom Cluster a Valid Construct in Adjunctive Treatment of Major Depressive Disorder?

Stauffer VL, Liu P, Goldberger C, Marangell LB, Nelson C, Gorwood P, Fava M.

J Clin Psychiatry. 2017 Mar;78(3):317-323. doi: 10.4088/JCP.15m09972.

Differentiating residual symptoms of depression from adverse events among patients initiating treatment with an antidepressant.

Freeman MP, Fisher L, Clain A, Rabbitt R, Pooley J, Baer L, Fava M.

Ann Clin Psychiatry. 2017 Feb;29(1):28-34.